Products for Research Use Only

Pemafibrate-d4

CAT: 0804-HY-17618S-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-17618S-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Pemafibrate-d4 is deuterated labeled Pemafibrate. Pemafibrate is a highly selective PPARα agonist, with an EC50 of 1 nM.
CAS Number
2924193-31-5
Product Name Alternative
(R) -K-13675-d4
UNSPSC
12352005
Target
Isotope-Labeled Compounds; PPAR
Type
Isotope-Labeled Compounds
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Others; Vitamin D Related/Nuclear Receptor
Applications
COVID-19-anti-virus
Field of Research
Inflammation/Immunology
Purity
99.80
Solubility
10 mM in DMSO
Smiles
O=C(O[2H])[C@@H](CC)OC1=CC=CC(CN(C2=NC3=CC=CC=C3O2)CCCOC4=CC=C(C=C4)OC([2H])([2H])[2H])=C1
Molecular Formula
C28H26D4N2O6
Molecular Weight
494.57
References & Citations
[1]Yamazaki Y, et al. Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists. Bioorg Med Chem Lett. 2007 Aug 15;17 (16) :4689-93. Epub2007 May 24.|[2]Honda Y, et al. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. Sci Rep. 2017 Feb 14;7:42477.|[3]Sairyo M, et al. A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice. J Atheroscler Thromb. 2018 Feb 1;25 (2) :142-152.|[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Alternative Products